BioWorld

May 27, 2009

MAP Gets Boost on Positive Phase III Migraine Study

Shares in MAP Pharmaceuticals Inc. spiked 185.7 percent Tuesday on the news that its Phase III migraine study of Levadex hit all four primary objectives. (BioWorld Today) Read More

Cytokinetics' Cardio Bet Pays Off with Amgen Option Exercise

Cancer, Depression Have Direct Link in Cytokines, Corticosterone

United Therapeutics Jumps on Adcirca Approval in PAH

Other News To Note

Clinic Roundup

Financings Roundup

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for July 31, 2026.

Illustration of dopamine signaling in the brain

New schizophrenia targets challenge trial design

BioWorld

The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...

News in brief

BioWorld Asia

BioWorld Asia briefs for July 28, 2026

AIDS 2026: New targets for metabolic dysfunction despite ART

BioWorld

Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...

Jingxin discloses new muscarinic and sigma receptor agonists

BioWorld Science

Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...